CytomX Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
CytomX Therapeutics, Inc. (CTMX) had Debt Securities, Available-for-sale, Amortized Cost of $336.45 million as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2018-11-06
- 2018-09-30: Debt Securities, Available-for-sale, Amortized Cost $336.45M.
- 2018-06-30: Debt Securities, Available-for-sale, Amortized Cost $334.76M.
- 2018-03-31: Debt Securities, Available-for-sale, Amortized Cost $351.32M.
- 2017-12-31: Debt Securities, Available-for-sale, Amortized Cost $361.99M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2018-09-30 | $336.45M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $334.76M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $351.32M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $361.99M 10-Q · filed 2018-11-06 | |
| 2017-09-30 | $321.23M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $63.14M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $76.94M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $167.84M 10-K · filed 2018-03-07 | $77.30M 10-Q · filed 2017-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |